#	Pagina
attuale pagina	/open-h2020/projects/201781/index.html

Opendata, web and dolomites

LDMBI

Low dose Molecular Breast Imaging for improved cancer detection in dense breast tissue.

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

LDMBI project word cloud

Explore the words cloud of the LDMBI project. It provides you a very rough idea of what is the project "LDMBI" about.

imaging feasibility false cancer screening difficulty add rate breast vs usa mammography 147 kromek first approximately tissue cancerous adoption innovative women diagnosed predict mammogram platform cancers molecular alarms biopsy guide dense detectors detection economic euros balance missed viability barriers 110 supplies thousand distinguishing commercialisation million tumours mbi breasts fewer diagnosis inability market specificity regulatory create sensitivity dose radiation technologies screened restricted sales 50 erroneously

Project "LDMBI" data sheet

The following table provides information about the project.

Coordinator	KROMEK LIMITED Organization address address: THOMAS WRIGHT WAY NETPARK city: SEDGEFIELD DURHAM postcode: TS21 3FD website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	http://www.kromek.com/index.php/horizon-2020
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-03-01 to 2016-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KROMEK LIMITED KROMEK LIMITED Organization address address: THOMAS WRIGHT WAY NETPARK city: SEDGEFIELD DURHAM postcode: TS21 3FD website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (SEDGEFIELD DURHAM)	coordinator	50˙000.00

Map

Project objective

The 50% of women with dense breast tissue who are currently screened for breast cancer by mammography have large numbers of cancers missed, and non-cancerous features erroneously diagnosed, due to the difficulty of a mammogram distinguishing tumours from dense breast tissue. In dense breasts, around 1 in 2 cancers is missed by mammography. Molecular Breast Imaging has much higher sensitivity (a better cancer detection rate) and specificity (fewer false alarms) than mammography, particularly for dense breasts. Its use as a screening technology is currently restricted due to its high radiation dose and inability to guide a biopsy. This feasibility study will investigate the technical, economic and regulatory viability of Kromek’s technology to being adopted in optimised diagnosis pathways. Kromek currently supplies detectors into the MBI market, and have a number of innovative platform technologies to add to the current offering to create a system to address these barriers to adoption. Work in this Phase 1 study will identify the dose vs cancer detection balance, to guide the application of the technologies to the market needs. We predict sales in the EU and USA of 147 million Euros in the first five years after commercialisation, which will help address the approximately 110 thousand women in Europe whose cancers in dense breasts are currently missed by mammography.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LDMBI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LDMBI" are provided by the European Opendata Portal: CORDIS opendata.